CL2023000629A1 - Partículas virales modificadas y usos de estas - Google Patents

Partículas virales modificadas y usos de estas

Info

Publication number
CL2023000629A1
CL2023000629A1 CL2023000629A CL2023000629A CL2023000629A1 CL 2023000629 A1 CL2023000629 A1 CL 2023000629A1 CL 2023000629 A CL2023000629 A CL 2023000629A CL 2023000629 A CL2023000629 A CL 2023000629A CL 2023000629 A1 CL2023000629 A1 CL 2023000629A1
Authority
CL
Chile
Prior art keywords
aav
particles
viral particles
modified viral
current therapeutic
Prior art date
Application number
CL2023000629A
Other languages
English (en)
Inventor
Kyratsous Christos
Sabin Leah
MOLLER-TANK Sven
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2023000629A1 publication Critical patent/CL2023000629A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se proporcionan las composiciones y métodos para adaptar partículas de virus adenoasociado (AAV) que comprenden cápsides de AAV de animal no primate, AAV remoto, o una de sus combinaciones. El AAV adaptado, en consecuencia, puede ser una plataforma de terapia génica viable para el tratamiento de un paciente que lo necesita, y puede ser particularmente útil en pacientes excluidos de modalidades de tratamiento actuales que implican partículas de AAV terapéuticas actuales debido a su alto título de anticuerpos contra las partículas de AAV terapéuticas actuales.
CL2023000629A 2019-05-24 2023-03-03 Partículas virales modificadas y usos de estas CL2023000629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962852791P 2019-05-24 2019-05-24

Publications (1)

Publication Number Publication Date
CL2023000629A1 true CL2023000629A1 (es) 2023-10-20

Family

ID=71094822

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021003096A CL2021003096A1 (es) 2019-05-24 2021-11-23 Partículas virales modificadas y usos de estas
CL2023000629A CL2023000629A1 (es) 2019-05-24 2023-03-03 Partículas virales modificadas y usos de estas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021003096A CL2021003096A1 (es) 2019-05-24 2021-11-23 Partículas virales modificadas y usos de estas

Country Status (18)

Country Link
US (1) US20220241430A1 (es)
EP (1) EP3976631A1 (es)
JP (1) JP2022533438A (es)
KR (1) KR20220011664A (es)
CN (2) CN113874386A (es)
AR (2) AR118997A1 (es)
AU (1) AU2020283537A1 (es)
BR (1) BR112021023692A2 (es)
CA (1) CA3140386A1 (es)
CL (2) CL2021003096A1 (es)
CO (1) CO2021017692A2 (es)
IL (1) IL288233A (es)
MA (1) MA56035A (es)
MX (1) MX2021014338A (es)
PE (1) PE20212357A1 (es)
SG (1) SG11202112917PA (es)
TW (1) TW202110869A (es)
WO (1) WO2020242984A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976631A1 (en) * 2019-05-24 2022-04-06 Regeneron Pharmaceuticals, Inc. Modified viral particles and uses thereof
WO2022187377A1 (en) * 2021-03-02 2022-09-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated viruses and methods and materials for making and using adeno-associated viruses
EP4314021A1 (en) * 2021-04-30 2024-02-07 Duke University Compositions comprising adeno-associated virus chimera capsid proteins and methods of using the same
CN117957325A (zh) * 2021-06-23 2024-04-30 迪诺治疗公司 衣壳变体及其使用方法
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0840797B1 (en) 1995-07-25 2014-09-03 Crucell Holland B.V. Methods and means for targeted gene delivery
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
JP4060531B2 (ja) 1998-05-28 2008-03-12 アメリカ合衆国 Ａａｖ５ベクターおよびその使用
JP4573437B2 (ja) 1998-11-05 2010-11-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス血清型１核酸配列、ベクターおよび同一物を含有する宿主細胞
NZ532635A (en) * 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
LT2954779T (lt) 2009-12-10 2019-05-27 Regeneron Pharmaceuticals, Inc. Pelės, gaminančios sunkiosios grandinės antikūnus
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
CN106459984B (zh) * 2014-03-10 2021-09-07 优尼科Ip有限公司 昆虫细胞中产生的进一步改善的aav载体
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015191508A1 (en) * 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
JP7372154B2 (ja) 2017-06-27 2023-10-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝物質をヒト細胞に標的化して導入するための指向性改変組換えウイルスベクターおよびその使用
SG11201911614XA (en) * 2017-06-27 2020-01-30 Regeneron Pharma Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells
EP3976631A1 (en) * 2019-05-24 2022-04-06 Regeneron Pharmaceuticals, Inc. Modified viral particles and uses thereof

Also Published As

Publication number Publication date
KR20220011664A (ko) 2022-01-28
BR112021023692A2 (pt) 2022-01-04
CL2021003096A1 (es) 2022-09-20
AR124119A2 (es) 2023-02-15
TW202110869A (zh) 2021-03-16
US20220241430A1 (en) 2022-08-04
MX2021014338A (es) 2022-01-06
WO2020242984A1 (en) 2020-12-03
AU2020283537A1 (en) 2021-12-16
WO2020242984A9 (en) 2021-01-14
MA56035A (fr) 2022-04-06
JP2022533438A (ja) 2022-07-22
CN114989267A (zh) 2022-09-02
AR118997A1 (es) 2021-11-17
SG11202112917PA (en) 2021-12-30
PE20212357A1 (es) 2021-12-17
IL288233A (en) 2022-01-01
CO2021017692A2 (es) 2022-01-17
CN113874386A (zh) 2021-12-31
CA3140386A1 (en) 2020-12-03
EP3976631A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
CL2023000629A1 (es) Partículas virales modificadas y usos de estas
CO2020004738A2 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
MX2018014573A (es) Vacuna contra el virus del zika.
CL2018003196A1 (es) Cápsides variantes de virus adenoasociados y métodos de uso de estas.
CO2017004290A2 (es) Composiciones y métodos para el silenciamiento de la expresión génica del virus de la hepatitis b
CL2018003769A1 (es) Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado.
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
ECSP16083000A (es) Terapia genica para la retinitis pigmentaria
EA201791199A1 (ru) Способ лечения болезни альцгеймера
EA201600476A1 (ru) Вариант вируса ppcc, клон кднк вируса ppcc европейского типа и их применение
CO2017007383A2 (es) Métodos para utilizar oligonucleótidos antisentido para smad7
AR104598A1 (es) Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
Ellerhoff et al. Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
Summerfield Factors involved in type I interferon responses during porcine virus infections
CL2023001650A1 (es) Tratamiento de la enfermedad de danon
EA201401352A1 (ru) Вакцина против вируса шмалленберга (sbv), способы ее получения и применения
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
EA202192459A1 (ru) Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста
Wilkinson LACK OF PROVEN EFFICACY: A LEGITIMATE REASON TO DENY ACCESS TO CELLULAR THERAPIES OR A BARRIER TO INNOVATIVE TRIALS AND THE DEVELOPMENT OF CURES?